Skip to main content
Caplight Logo









KLISBio

KLISBio

Private
BressoHealthcare & Life Scienceshttps://klis.bio/

Last Round

Grant

Feb 28, 2024

Total Funding Raised

$11.34M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

KLISBio is a biotechnology company that develops implantable regenerative medical solutions powered by silk fibroin for soft tissue repair.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Advanced Materials, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

regenerative medicinesilk fibroinnerve regenerationbiomaterialsmedical devicessoft tissue repairnerve guidebiointegrative implantstissue engineeringsurgical implantsbiotechmedtechscaffold technologyvascular graftbone graft substitute

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

KLISBio Comparables

Compare KLISBio with similar companies based on industry and business-model similarity.

KLISBio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Regenity Biosciences
79%
Integra LifeSciences Holdings Corporation
75%
Solventum Corp.
71%

KLISBio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantFeb 28, 2024
Series AApr 21, 2016
AngelDec 1, 2015
GrantDec 5, 2014

Key People

Founding team and executive leadership

Antonio Alessandrino

Founder CTO Board Member

Founding Team

Gabriele Grecchi

Chief Executive Officer Co-Founder

Founding Team

KLISBio Investors

Notable investors and investment history

KLISBio investors
InvestorRounds
European Innovation Council FundGrant
Principia SGRSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 18, 2026

    Monthly visitors increased 1052% MoM, from 31 to 357.

  • Apr 21, 2016

    $8M round led by Principia SGR

KLISBio Filings

Explore SEC and related filing metadata, where available.

KLISBio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about KLISBio's valuation, stock price, and market status.

Is KLISBio a public or private company?

KLISBio is a private company.

What is the current stock price of KLISBio?

KLISBio is a private company with no public stock price. No recent secondary market data is available.

How much is KLISBio worth (valuation)?

Valuation information for KLISBio is not publicly available.

Can I buy KLISBio stock?

KLISBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was KLISBio's last funding round?

KLISBio's most recent funding round was Grant on February 28, 2024.

Who are the main investors in KLISBio?

Key investors in KLISBio include European Innovation Council, Principia SGR.

Will KLISBio IPO soon?

No public IPO plans have been announced for KLISBio.

How can I track KLISBio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor KLISBio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBresso
Employee Range22
Year Founded2014
Last FundingFeb 28, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?